Department of Natural Sciences, Middlesex University London, London, UK.
Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland.
Proc Biol Sci. 2021 Feb 10;288(1944):20202716. doi: 10.1098/rspb.2020.2716. Epub 2021 Feb 3.
Arthropods can produce a wide range of antifungal compounds, including specialist proteins, cuticular products, venoms and haemolymphs. In spite of this, many arthropod taxa, particularly eusocial insects, make use of additional antifungal compounds derived from their mutualistic association with microbes. Because multiple taxa have evolved such mutualisms, it must be assumed that, under certain ecological circumstances, natural selection has favoured them over those relying upon endogenous antifungal compound production. Further, such associations have been shown to persist versus specific pathogenic fungal antagonists for more than 50 million years, suggesting that compounds employed have retained efficacy in spite of the pathogens' capacity to develop resistance. We provide a brief overview of antifungal compounds in the arthropods' armoury, proposing a conceptual model to suggest why their use remains so successful. Fundamental concepts embedded within such a model may suggest strategies by which to reduce the rise of antifungal resistance within the clinical milieu.
节肢动物可以产生广泛的抗真菌化合物,包括专业蛋白质、表皮产物、毒液和血淋巴。尽管如此,许多节肢动物类群,特别是真社会性昆虫,利用与其共生微生物衍生的额外抗真菌化合物。由于多个类群已经进化出这种共生关系,因此可以假设,在某些生态环境下,自然选择使它们比依赖内源性抗真菌化合物产生的物种更具优势。此外,这些关联已经被证明可以持续存在于特定的致病性真菌拮抗物超过 5000 万年,这表明尽管病原体有能力产生抗药性,但所使用的化合物仍然有效。我们简要概述了节肢动物防御机制中的抗真菌化合物,并提出了一个概念模型,以说明为什么它们的使用仍然如此成功。这样的模型中所包含的基本概念可能会为减少临床环境中抗真菌药物耐药性的出现提供策略。